X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (35984) 35984
Magazine Article (194) 194
Book Chapter (174) 174
Dissertation (43) 43
Conference Proceeding (31) 31
Publication (23) 23
Book / eBook (22) 22
Reference (9) 9
Web Resource (7) 7
Book Review (2) 2
Data Set (1) 1
Government Document (1) 1
Journal / eJournal (1) 1
Newsletter (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (26195) 26195
science & technology (21472) 21472
life sciences & biomedicine (21235) 21235
angiotensin-converting enzyme inhibitors - therapeutic use (18500) 18500
male (16080) 16080
female (12148) 12148
animals (9595) 9595
middle aged (9014) 9014
angiotensin-converting enzyme inhibitors - pharmacology (8727) 8727
cardiovascular system & cardiology (8081) 8081
hypertension - drug therapy (8027) 8027
aged (7811) 7811
adult (5648) 5648
blood pressure - drug effects (5478) 5478
cardiac & cardiovascular systems (5329) 5329
angiotensin-converting enzyme inhibitors (5067) 5067
rats (4960) 4960
hypertension (4741) 4741
abridged index medicus (4580) 4580
antihypertensive agents - therapeutic use (4542) 4542
pharmacology & pharmacy (4282) 4282
heart failure - drug therapy (4117) 4117
angiotensin-converting enzyme inhibitors - adverse effects (4084) 4084
treatment outcome (3819) 3819
adrenergic beta-antagonists - therapeutic use (3812) 3812
angiotensin-converting enzyme inhibitors - administration & dosage (3695) 3695
drug therapy, combination (3517) 3517
peripheral vascular disease (3456) 3456
risk factors (3336) 3336
angiotensin (3093) 3093
general & internal medicine (3079) 3079
renin-angiotensin system - drug effects (3053) 3053
medicine, general & internal (2938) 2938
ace inhibitors (2937) 2937
hypertension - physiopathology (2932) 2932
heart failure (2836) 2836
calcium channel blockers - therapeutic use (2526) 2526
time factors (2388) 2388
blood pressure (2345) 2345
diuretics - therapeutic use (2247) 2247
enzymes (2180) 2180
angiotensin receptor antagonists (2054) 2054
captopril - pharmacology (2045) 2045
hypertension - complications (2044) 2044
urology & nephrology (2014) 2014
aged, 80 and over (1997) 1997
drug therapy (1988) 1988
angiotensin ii type 1 receptor blockers - therapeutic use (1947) 1947
double-blind method (1891) 1891
dose-response relationship, drug (1716) 1716
enalapril - therapeutic use (1714) 1714
follow-up studies (1629) 1629
heart failure - physiopathology (1622) 1622
antihypertensive agents - pharmacology (1608) 1608
retrospective studies (1559) 1559
randomized controlled trials as topic (1512) 1512
clinical trials as topic (1493) 1493
captopril - therapeutic use (1476) 1476
prospective studies (1458) 1458
angiotensin receptor antagonists - therapeutic use (1429) 1429
renin-angiotensin system (1422) 1422
renin-angiotensin system - physiology (1414) 1414
hemodynamics - drug effects (1409) 1409
captopril (1355) 1355
angiotensin-converting enzyme inhibitor (1344) 1344
myocardial infarction - drug therapy (1330) 1330
care and treatment (1323) 1323
angiotensin converting enzyme inhibitors (1319) 1319
mortality (1316) 1316
peptidyl-dipeptidase a - metabolism (1310) 1310
prognosis (1304) 1304
enalapril - pharmacology (1292) 1292
kidney - drug effects (1292) 1292
medicine & public health (1208) 1208
diabetes (1192) 1192
renin - blood (1170) 1170
angiotensin ii (1160) 1160
rats, inbred shr (1138) 1138
diuretics (1137) 1137
research (1129) 1129
enzyme inhibitors (1126) 1126
rats, sprague-dawley (1122) 1122
rats, wistar (1120) 1120
chronic disease (1114) 1114
cardiovascular disease (1113) 1113
adolescent (1112) 1112
analysis (1111) 1111
antihypertensive agents - administration & dosage (1107) 1107
disease progression (1087) 1087
enalapril (1087) 1087
heart rate - drug effects (1060) 1060
antihypertensive agents - adverse effects (1029) 1029
cardiology (1024) 1024
health aspects (1013) 1013
physiology (966) 966
disease models, animal (929) 929
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (908) 908
angiotensin-converting enzyme inhibitors - chemistry (902) 902
chemistry (898) 898
heart failure - mortality (896) 896
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (32732) 32732
German (976) 976
Japanese (975) 975
French (720) 720
Russian (663) 663
Spanish (381) 381
Italian (262) 262
Chinese (229) 229
Polish (196) 196
Portuguese (181) 181
Danish (86) 86
Hungarian (82) 82
Czech (77) 77
Dutch (77) 77
Swedish (63) 63
Norwegian (58) 58
Finnish (30) 30
Korean (29) 29
Romanian (26) 26
Slovak (25) 25
Hebrew (22) 22
Ukrainian (22) 22
Turkish (20) 20
Serbian (18) 18
Croatian (14) 14
Lithuanian (14) 14
Persian (6) 6
Bosnian (4) 4
Bulgarian (4) 4
Slovenian (3) 3
Belarusian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet (British edition), ISSN 0140-6736, 2011, Volume 378, Issue 9798, pp. 1231 - 1243
Summary Background Although most cardiovascular disease occurs in low-income and middle-income countries, little is known about the use of effective secondary... 
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Data Collection | Secondary Prevention | Stroke - drug therapy | Urban Population | Antihypertensive Agents - therapeutic use | Drug Utilization | Cardiovascular Agents - therapeutic use | Developed Countries | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Rural Population | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Coronary Disease - drug therapy | Adult | Female | Aged | Developing Countries | Platelet Aggregation Inhibitors - therapeutic use | Adrenergic beta-Antagonists - therapeutic use | Care and treatment | Research | Cardiovascular diseases | Health aspects | Cardiovascular agents | Studies | Low income groups | Stroke | Households | Socioeconomic factors | Data collection | Cardiovascular disease | Epidemiology | Economic development | Community | Drug use | Index Medicus | Abridged Index Medicus | Antihypertensive Agents/therapeutic use | Angiotensin-Converting Enzyme Inhibitors/therapeutic use | Cardiovascular Agents/therapeutic use | Coronary Disease/drug therapy | Cardiovascular Diseases/prevention & control | Platelet Aggregation Inhibitors/therapeutic use | Stroke/drug therapy | MEDICIN OCH HÄLSOVETENSKAP | Adrenergic beta-Antagonists/therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use | MEDICAL AND HEALTH SCIENCES
Journal Article
The New England journal of medicine, ISSN 1533-4406, 09/2014, Volume 371, Issue 11, pp. 993 - 1004
The angiotensin receptor–neprilysin inhibitor LCZ696 was compared with the ACE inhibitor enalapril in patients with advanced heart failure. LCZ696 was superior... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Double-Blind Method | Humans | Middle Aged | Kaplan-Meier Estimate | Aminobutyrates - adverse effects | Hospitalization - statistics & numerical data | Male | Aminobutyrates - therapeutic use | Enalapril - therapeutic use | Enalapril - adverse effects | Heart Failure - drug therapy | Stroke Volume | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Neprilysin - antagonists & inhibitors | Female | Tetrazoles - therapeutic use | Aged | Tetrazoles - adverse effects | Angiotensin Receptor Antagonists - therapeutic use | Drug Combinations | Angiotensin Receptor Antagonists - adverse effects | Heart Failure - mortality | Heart failure | Enalapril | Patient outcomes | Angiotensin | Enalaprilat | Dosage and administration | Research | Drug therapy | Enzymes | Statistical analysis | Mortality | Angioedema | Hypotension | Cough | Studies | Hyperkalemia | Death | Neprilysin | Heart diseases | Index Medicus | Abridged Index Medicus | MORTALITY | SURVIVAL | RANDOMIZED-TRIAL | RECEPTOR | Klinisk medicin | NEUTRAL ENDOPEPTIDASE INHIBITION | NATRIURETIC-PEPTIDE | Medicine | Clinical Medicine | CONVERTING ENZYME-INHIBITION | MORBIDITY | EJECTION FRACTION | General & Internal | DOUBLE-BLIND
Journal Article
The New England journal of medicine, ISSN 1533-4406, 07/2009, Volume 361, Issue 1, pp. 40 - 51
This study aimed to determine whether early administration of drugs that block the renin–angiotensin system slows the progression of change in glomerular... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Retina - drug effects | Angiotensin II Type 1 Receptor Blockers - adverse effects | Follow-Up Studies | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Male | Albuminuria | Angiotensin II Type 1 Receptor Blockers - pharmacology | Enalapril - therapeutic use | Enalapril - adverse effects | Mesangial Cells - drug effects | Glomerular Filtration Rate - drug effects | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Adult | Female | Angiotensin-Converting Enzyme Inhibitors - pharmacology | Diabetic Nephropathies - prevention & control | Double-Blind Method | Diabetes Mellitus, Type 1 - physiopathology | Kidney Glomerulus - drug effects | Diabetes Mellitus, Type 1 - pathology | Kaplan-Meier Estimate | Losartan - pharmacology | Logistic Models | Kidney Glomerulus - pathology | Disease Progression | Diabetes Mellitus, Type 1 - drug therapy | Diabetic Retinopathy - prevention & control | Enalapril - pharmacology | Losartan - therapeutic use | Mesangial Cells - pathology | Losartan - adverse effects | Renin-Angiotensin System - drug effects | Retina - pathology | Diabetic retinopathy | Control | Usage | Enalapril | Type 1 diabetes | Patient outcomes | Losartan | Enalaprilat | Drug therapy | Kidneys | Diabetes | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 09/2008, Volume 359, Issue 12, pp. 1225 - 1237
In a multicenter trial, 20,332 patients who had recently had an ischemic stroke were randomly assigned to receive either telmisartan or placebo. All patients... 
MORTALITY | HIGH-RISK PATIENTS | DESIGN | RAMIPRIL | RATIONALE | DOUBLE-BLIND | VASCULAR EVENTS | COMBINATION | UMCG Approved | BLOOD-PRESSURE | RANDOMIZED TRIAL | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Benzoates - adverse effects | Myocardial Infarction - epidemiology | Benzoates - therapeutic use | Follow-Up Studies | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Secondary Prevention | Heart Failure - prevention & control | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Treatment Failure | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Blood Pressure - drug effects | Benzimidazoles - adverse effects | Heart Failure - epidemiology | Benzimidazoles - therapeutic use | Stroke - prevention & control | Kaplan-Meier Estimate | Stroke - drug therapy | Diabetes Mellitus - epidemiology | Creatinine - blood | Potassium - blood | Aged | Myocardial Infarction - prevention & control | Stroke (Disease) | Prevention | Usage | Health aspects | Telmisartan | Medical research | Stroke | Blood pressure | Index Medicus | Abridged Index Medicus | Blood Pressure | Creatinine | Recurrence | Benzimidazoles | Cardiovascular Diseases | Benzoates | Diabetes Mellitus | Geriatry and gerontology | Life Sciences | Human health and pathology | Myocardial Infarction | Angiotensin-Converting Enzyme Inhibitors | Heart Failure | Potassium | Cardiology and cardiovascular system | Original | Benzimidazoles/adverse effects/therapeutic use | Diabetes Mellitus/epidemiology | Angiotensin-Converting Enzyme Inhibitors/adverse effects/therapeutic use | Recurrence/prevention & control | Stroke/drug therapy/prevention & control | MEDICIN OCH HÄLSOVETENSKAP | Creatinine/blood | Potassium/blood | Blood Pressure/drug effects | Cardiovascular Diseases/epidemiology/mortality/prevention & control | Benzoates/adverse effects/therapeutic use | Myocardial Infarction/epidemiology/prevention & control | Kaplan-Meiers Estimate | MEDICAL AND HEALTH SCIENCES | Heart Failure/epidemiology/prevention & control
Journal Article